Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Nivolumab neoadjuvante e ipilimumab em NSCLC ressecável (Galaxy 3) (GALAXY 3)

5 de novembro de 2026 atualizado por: Shuben Li, The First Affiliated Hospital of Guangzhou Medical University

Nivolumab neoadjuvante e ipilimumab em câncer de pulmão de células não pequenas ressecáveis

Neoadjuvant immunotherapy followed by surgery has emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, conventional chemotherapy components may increase treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1 expression <1% remains to be improved. Emerging evidence has demonstrated that the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) provides superior responses in the treatment of advanced NSCLC. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC.

Visão geral do estudo

Status

Recrutamento

Intervenção / Tratamento

Descrição detalhada

Lung cancer remains the leading cause of cancer-related death globally. Neoadjuvant immunotherapy followed by surgery has been emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). Numerous clinical trials highlighted the efficacy of preoperative immunochemotherapy, including remarkably shrinking the primary lesion, eliminating micrometastases and ultimately contributing to survival outcomes. Notably, studies also demonstrated neoadjuvant immunochemotherapy increased the access of modified surgery and enhanced survival prognosis of patients with locally advanced NSCLC (IIIB).

Despite these advances, certain limitations remain. Conventional chemotherapy components may elevate treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1<1% remained to be improve. Emerging evidences demonstrated that nivolumab (anti-PD-1) combine with ipilimumab (antiCTLA-4) provided superior response for the treatment of advanced NSCLC patients. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC. The study will enroll 69 eligible participants, with the primary endpoint being pathological complete response (pCR) rate following neoadjuvant therapy.

Tipo de estudo

Intervencional

Inscrição (Estimado)

69

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Guangzhou, China, 510120
        • Recrutamento
        • First Affiliated Hospital of Guangzhou Medical University
        • Contato:
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 80 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Informed consent must be signed.
  2. At least 18 years of age.
  3. Histologically or cytologically confirmed non-small cell lung cancer (without EGFR, ALK mutation).
  4. Have measurable and clinical stage II-IIIA with no known PD-L1 expression or PD-L1 ≤ 1%.
  5. disease eligible for surgery.
  6. No previous systematic therapy or radiotherapy.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  8. At least one measurable lesion.
  9. No major organ dysfunction, including liver, kidney, and cardiac function.

Exclusion Criteria:

  1. Patients with active autoimmune disease or history of autoimmune disease.
  2. Patients have received other treatment for non-small cell lung cancer or for any other malignancy.
  3. History of allergy to study drug components.
  4. Pregnant or breast-feeding.
  5. Any mental or psychological condition that would prevent the patient from completing the study or understanding the patient information.
  6. Patients who have other malignancies.
  7. History of major surgery or serious injury within the past 3 months.
  8. HIV, HBV, HCV infection or active pulmonary tuberculosis.
  9. Vaccination within 4 weeks prior to the start of the study.
  10. Presence of underlying medical conditions that, in the investigator's judgment, could increase the risk associated with study drug administration or interfere with the assessment of toxicity and adverse events.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Neoadjuvant treatment

Patients with IIA-IIIB NSCLC will received 2-3 cycles of neoadjuvant Nivolumab (3 mg/kg intravenously (i.v.), every 3 week) plus Ipilimumab (1 mg/kg i.v., every 6 week).

Surgery will be performed within 4 to 6 weeks after completion of preoperative therapy.

After the second cycles treatment, contrast-enhanced chest CT will be performed to evaluate the tumor.

This study evaluates the safety and efficacy of neoadjuvant nivolumab plus ipilimumab for IIA-IIIB NSCLC. Based on preliminary trial results, this study proposes a new treatment regimen.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Pathological Complete Response (PCR)
Prazo: Within 2 weeks after surgery

Pathological complete response is predefined as no residual viable tumor cells in primary tumor and lymph nodes.

Within 2 weeks after surgery

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
3-year Event-Free Survival (3-year EFS)
Prazo: From neoadjuvant treatment to the date of death, recurrence, progression, or the last follow-up (assessed up to 3 years).

The starting point for EFS was the initiation of neoadjuvant treatment. The endpoint for EFS was defined as the date of death, recurrence, progression, or the last follow-up.

From neoadjuvant treatment to the date of death, recurrence, progression, or the last follow-up (assessed up to 3 years).
Major Pathological Response (MPR)
Prazo: Within 2 weeks after surgery

Major pathological response defined as less than 10% of viable tumor cells in primary tumor.

Within 2 weeks after surgery
Safety (Rate of grade 3 and higher grade treatment-related adverse events (TRAEs))
Prazo: Between the last dose of neoadjuvant treatment and surgery (assessed up to 30 days)

Adverse events will be evaluated and recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).

Between the last dose of neoadjuvant treatment and surgery (assessed up to 30 days)
Radiological Response
Prazo: Between the last dose of neoadjuvant treatment and surgery

Radiographic response will be evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

Between the last dose of neoadjuvant treatment and surgery
Postoperative complications
Prazo: After the surgery assess to 90 days

Postoperative complications will be evaluated and recorded after the surgery following Clavien-Dindo grade. The minimum and maximum values were grade I-V, and the higher scores mean a worse outcomes.

After the surgery assess to 90 days
Intraoperative bleeding
Prazo: Up to approximately 20 weeks

Intraoperative bleeding was assessed and recorded by the surgical team. Blood loss was estimated by measuring suction canister volume and weighing surgical sponges, subtracting irrigation fluid.

Up to approximately 20 weeks
The Quality of Life
Prazo: From the Day 1 to at least 90 days after surgery

The quality of life will be evaluated and recorded according to the EORTC QLQ-C30. The minimum and maximum values were 0-100, and the higher scores mean a better outcome.

From the Day 1 to at least 90 days after surgery
Duration of surgery
Prazo: Up to approximately 20 weeks

Duration of surgery is the time spent in surgery.

Up to approximately 20 weeks
Hospital Stay
Prazo: Up to approximately 20 weeks

Hospital Stay is the length of inpatient time spent in hospital.

Up to approximately 20 weeks
Feasibility (Completion rate of neoadjuvant treatment and surgery)
Prazo: From date of treatment allocation until surgery, assessed up to 5 months

Propotion of patients who complete neoadjuvant treatment and receive surgery within 42 days after neoadjuvant treatment

From date of treatment allocation until surgery, assessed up to 5 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

19 de junho de 2025

Conclusão Primária (Estimado)

31 de março de 2030

Conclusão do estudo (Estimado)

31 de outubro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

30 de março de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de abril de 2025

Primeira postagem (Real)

15 de abril de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

9 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

5 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever